Abstract 2531: Genomic landscape of breast cancer patients in Korea: Early data from K-MASTER project

2019 ◽  
Author(s):  
Jae Sook Sung ◽  
Hee-Joon Chung ◽  
Yoon Ji Choi ◽  
Won Jin Chang ◽  
Jung Yoon Choi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Data ◽  
Breast Cancer Patients ◽  
Genomic Landscape

Abstract 2531: Genomic landscape of breast cancer patients in Korea: Early data from K-MASTER project

2019 ◽  
Author(s):  
Jae Sook Sung ◽  
Hee-Joon Chung ◽  
Yoon Ji Choi ◽  
Won Jin Chang ◽  
Jung Yoon Choi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Data ◽  
Breast Cancer Patients ◽  
Genomic Landscape

Abstract GS1-07: The genomic landscape of 501 metastatic breast cancer patients

2019 ◽  
Author(s):  
L Angus ◽  
SM Wilting ◽  
J van Riet ◽  
M Smid ◽  
TG Steenbruggen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Genomic Landscape

scholarly journals Genomic landscape of extraordinary responses in metastatic breast cancer

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Sun Min Lim ◽  
Eunyoung Kim ◽  
Kyung Hae Jung ◽  
Sora Kim ◽  
Ja Seung Koo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Clinical Samples ◽  
Breast Cancer Patients ◽  
Single Nucleotide Variants ◽  
Mutational Burden ◽  
Whole Exome ◽  
Genomic Landscape

AbstractExtreme responders to anticancer therapy are rare among advanced breast cancer patients. Researchers, however, have yet to investigate treatment responses therein on the whole exome level. We performed whole exome analysis to characterize the genomic landscape of extreme responders among metastatic breast cancer patients. Clinical samples were obtained from breast cancer patients who showed exceptional responses to anti-HER2 therapy or hormonal therapy and from those who did not. Matched breast tumor tissue (somatic DNA) and blood samples (germline DNA) were collected from a total of 30 responders and 15 non-responders. Whole exome sequencing using Illumina HiSeq2500 was performed for all 45 patients (90 samples). Somatic single nucleotide variants (SNVs), indels, and copy number variants (CNVs) were identified for the genomes of each patient. Group-specific somatic variants and mutational burden were statistically analyzed. Sequencing of cancer exomes for all patients revealed 1839 somatic SNVs (1661 missense, 120 nonsense, 43 splice-site, 15 start/stop-lost) and 368 insertions/deletions (273 frameshift, 95 in-frame), with a median of 0.7 mutations per megabase (range, 0.08 to 4.2 mutations per megabase). Responders harbored a significantly lower nonsynonymous mutational burden (median, 26 vs. 59, P = 0.02) and fewer CNVs (median 13.6 vs. 97.7, P = 0.05) than non-responders. Multivariate analyses of factors influencing progression-free survival showed that a high mutational burden and visceral metastases were significantly related with disease progression. Extreme responders to treatment for metastatic breast cancer are characterized by fewer nonsynonymous mutations and CNVs.

Bisphosphonates in Breast Cancer Patients with Skeletal Metastases

1994 ◽  
Vol 8 (1) ◽  
pp. 153-163 ◽  
Author(s):  
Charles L. Shapiro
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Skeletal Metastases ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document